Study design (if review, criteria of inclusion for studies)
Single centre, RCT, double-blind, placebo controlled, cross-over design, 4 weeks.
Participants
Diagnosed CF in a stable clinical state infected with B. cepacia. 20 participants. Age, mean 23.6 (range 17 - 37)
Interventions
Nebulizer CR50, Ventstream at flow 6-7 L/min Inhaled 2% Taurolidine 4ml or 0.9% saline 4ml twice daily for 4 weeks, then cross-over with 2 week washout
Outcome measures
B. cepacia and P. aeruginosa colony counts. FEV1, FVC, symptom questionnaire.
Main results
There was no change in B. cepacia colony counts or spirometry, nor symptom scores.
Authors' conclusions
although taurolidine is well tolerated in nebulized form, in this study it had no in vivo anti-B. cepacia activity.